Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 10, 2026
DFEN ETF Climbs +17% Over 30 Days on Defense Sector Momentum

DFEN ETF Climbs +17% Over 30 Days on Defense Sector Momentum

Key Takeaways

  • DFEN surged approximately 17% over the past 30 days, driven by a powerful rally in aerospace and defense stocks.
  • The quarterly performance was a more modest gain of roughly 3%, reflecting earlier weakness followed by a sharp recovery.
  • Historic NATO defense spending commitments, a proposed $1.5 trillion U.S. defense budget for fiscal 2027, and major weapons contracts fueled the sector-wide advance.
  • Top holdings GE Aerospace, RTX, and Boeing posted strong gains, amplified by the fund's 3x daily leveraged structure.
  • As a leveraged ETF, DFEN magnifies daily index moves and is designed for short-term trading, not long-term buy-and-hold strategies.

DFEN Overview and Portfolio Exposure

The Direxion Daily Aerospace & Defense Bull 3X ETF seeks daily investment results, before fees and expenses, of 300% of the performance of the Dow Jones U.S. Select Aerospace & Defense Index. The fund is a passively managed, leveraged ETF that uses swap agreements and other financial instruments to achieve its daily target. It carries a net expense ratio of 0.96%.

The underlying index is composed of U.S.-listed aerospace and defense companies selected on a float-adjusted, market capitalization-weighted basis. The portfolio is concentrated in the industrials sector, with virtually all equity exposure tied to aerospace and defense. Top holdings include GE Aerospace, RTX (formerly Raytheon Technologies), Boeing, General Dynamics, Howmet Aerospace, L3Harris Technologies, Lockheed Martin, Northrop Grumman, TransDigm Group, and Axon Enterprise. This concentrated exposure means the ETF's performance is heavily influenced by a handful of large-cap defense primes, making it particularly sensitive to government procurement cycles and geopolitical developments.

DFEN Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, DFEN climbed approximately 17%, rallying from around $64.59 in mid-June to roughly $75.67 by mid-July. The advance was not linear; the ETF experienced several sharp upward moves interspersed with bouts of profit-taking, consistent with the amplified volatility expected from a 3x leveraged product. I also checked this using Tickeron’s AI Screener to see how the ETF compares to others in the industry.

In contrast, the quarterly performance was far more subdued at roughly 3%. The ETF traded as low as approximately $55.90 in late April before recovering. This pattern—a period of weakness earlier in the quarter followed by a strong rally in June and July—highlights how quickly sentiment can shift in the defense sector when policy catalysts emerge. The 3x daily leverage magnified both the earlier drawdown and the subsequent rebound, underscoring the compounding effects that can cause leveraged ETF returns to deviate significantly from simple multiples of the index over periods longer than a single day.

What Drove DFEN Price in the Last 30 Days

The primary catalyst was a surge in defense spending commitments and contract awards that lifted the entire aerospace and defense sector. In late June, the U.S. Department of Defense awarded Lockheed Martin a $35.3 billion multiyear contract for THAAD missile production. RTX secured approximately $400 million for medium-range air-to-air missiles, building on earlier Tomahawk missile contracts. Boeing received a $2 billion U.S. Space Force contract for communications satellites.

The NATO Ankara Summit in early July 2026 added further momentum. Allies announced $3 billion in new defense deals and joint ventures, while President Trump pressed member nations to accelerate toward the 5% of GDP defense spending target by 2035. The proposed U.S. fiscal year 2027 defense budget of $1.5 trillion—a 44% increase over 2026 enacted levels—reinforced expectations of a multi-year procurement upcycle.

Investor enthusiasm also extended beyond traditional hardware. Growing focus on AI-enabled battlefield technology, autonomous systems, and space-based defense assets broadened the rally. GE Aerospace, the index's largest constituent, benefited from strong commercial aerospace demand and defense engine orders. The combination of these factors created a powerful tailwind that DFEN's 3x leverage amplified significantly.

What Drove DFEN Performance Over the Last Quarter

The broader three-month trend reflects a sector that experienced turbulence earlier in the quarter before policy catalysts reignited momentum. In April and early May, aerospace and defense stocks faced headwinds from broader market volatility, uncertainty around government funding timelines, and profit-taking after a strong first-quarter 2026 performance. The underlying index declined, and DFEN's leverage magnified the move lower.

The recovery that began in late May and accelerated through June and July was driven by a shift in the macroeconomic and policy landscape. As defense budget proposals became more concrete and geopolitical tensions remained elevated—particularly in the Middle East and Eastern Europe—institutional investors rotated back into the sector. The quarterly performance, while modestly positive at roughly 3%, masks significant intra-quarter volatility that is characteristic of leveraged ETF products. Fund flows data indicated some net outflows during the quarter, suggesting that traders may have been taking profits or reducing exposure during periods of uncertainty, even as the underlying sector fundamentals strengthened.

Using Tickeron’s AI Screener for Defense Sector Research

When evaluating opportunities in concentrated sectors like aerospace and defense, I find Tickeron’s AI Screener to be a practical addition to the research process. The tool applies artificial intelligence to scan thousands of stocks and ETFs across technical indicators, fundamental metrics, volatility patterns, price formations, and AI-generated signals. Users can filter by industry, market capitalization, performance characteristics, and custom parameters to identify securities that align with specific criteria. In the context of defense contractors and related industrials, it helps surface ideas more efficiently than manual methods, supporting a more structured approach to monitoring the names that drive funds like DFEN.

DFEN ETF Outlook: What Investors Should Watch Next

The trajectory of defense spending remains the single most important factor for DFEN. Investors should monitor whether the proposed $1.5 trillion fiscal 2027 defense budget progresses through Congress and whether NATO allies follow through on spending commitments made at the Ankara Summit. Additional multiyear procurement contracts, particularly for missiles, air defense systems, and space-based assets, would provide further revenue visibility for the sector's largest companies.

Geopolitical developments will continue to influence sentiment. Tensions in the Middle East, the ongoing strategic competition with China, and Russia's military posture all have the potential to drive further government spending. Conversely, any diplomatic breakthroughs or de-escalation could temper the urgency behind current budget proposals.

Interest rate expectations and broader macroeconomic conditions also matter. Defense stocks are not immune to market-wide risk-off moves, and DFEN's 3x leverage means any sector pullback would be amplified. The fund's daily reset mechanism makes it unsuitable for passive, long-term holding strategies, as compounding and volatility decay can erode returns over extended periods. Investors using DFEN should actively monitor position sizes, have clearly defined risk management parameters, and stay attuned to the policy and geopolitical calendar that increasingly drives this sector.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: DFEN

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


Momentum Indicator for DFEN turns positive, indicating new upward trend

DFEN saw its Momentum Indicator move above the 0 level on July 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for DFEN just turned positive on July 27, 2026. Looking at past instances where DFEN's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

DFEN moved above its 50-day moving average on July 30, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for DFEN crossed bullishly above the 50-day moving average on July 31, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The 50-day moving average for DFEN moved above the 200-day moving average on July 09, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DFEN advanced for three days, in of 346 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 307 cases where DFEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for DFEN moved out of overbought territory on July 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DFEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DFEN broke above its upper Bollinger Band on July 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Spirit Aerosystems Holdings (null:SPR).

Industry description

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Dow Jones U.S. Select Aerospace & Defense Index. The fund invests at least 80% of its net assets (plus borrowing for investment purposes) in financial instruments, such as swap agreements, securities of the index, and exchange-traded funds ("ETFs") that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index attempts to measure the performance of the aerospace and defense industry of the U.S. equity market. The fund is non-diversified.

Market Cap

The average market capitalization across the Direxion Dly Aerospace&Def Bl 3X ShsETF ETF is 52.76B. The market cap for tickers in the group ranges from 592.95M to 383.98B. GE holds the highest valuation in this group at 383.98B. The lowest valued company is RGR at 592.95M.

High and low price notable news

The average weekly price growth across all stocks in the Direxion Dly Aerospace&Def Bl 3X ShsETF ETF was 30%. For the same ETF, the average monthly price growth was 21%, and the average quarterly price growth was 63%. KTOS experienced the highest price growth at 24%, while RGR experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the Direxion Dly Aerospace&Def Bl 3X ShsETF ETF was -8%. For the same stocks of the ETF, the average monthly volume growth was -11% and the average quarterly volume growth was -29%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 56
Price Growth Rating: 47
SMR Rating: 63
Profit Risk Rating: 51
Seasonality Score: -41 (-100 ... +100)
View a ticker or compare two or three
DFEN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Leveraged Equity
Address
Direxion Shares ETF Trust33 Whitehall Street,10th FloorNew York
Phone
866-476-7523
Web
http://www.direxioninvestments.com/
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.